Liver Cancer
23 January 2026
Introduction
Liver cancer was the fifth commonest cancer in Hong Kong and accounted for 4.5% of all new cancer cases in 2023. It was the fourth commonest cancer in men and the twelfth commonest cancer in women.
Incidence
There were 1 700 new cases of liver cancer in 2023, with 1 273 male cases and 427 female cases. The male to female ratio of incidence was about 3.0 to 1. The crude incidence rates of liver cancer were 37.1 for males and 10.4 for females per 100 000 population of respective sex. The age-standardised incidence rates* of liver cancer were 17.1 for males and 4.7 for females per 100 000 standard population.
Trend of incidence
The age-standardised incidence rates of liver cancer of both sexes, males and females all had a downward trend over the past 41 years (average annual percentage change (AAPC)# between 1983 and 2023: -2.4%, -2.5% and -2.2% respectively) and over the past 10 years (AAPC between 2014 and 2023: -3.9%, -4.3% and -3.9% respectively).
Number of new cases and crude incidence rate of liver cancer by sex, 1983 to 2000 （View）
Number of new cases and crude incidence rate of liver cancer by sex, 2001 to 2023 （View）
Age-standardised incidence rate of liver cancer by sex, 1983 to 2023
| Notes : | Classification of diseases and causes of death is based on the International Statistical Classification of Diseases and Related Health Problems (ICD) 10th Revision from 2001 onwards. Figures from 2001 onwards may not be comparable with figures for previous years which were compiled based on the ICD 9th Revision. |
|
| * | Age-standardised incidence rates are compiled based on the world standard population specified in GPE Discussion Paper Series: No.31, EIP/GPE/EBD, World Health Organization, 2001. |
|
| # | AAPC of age-standardised incidence rates is a summary measure of the trends in the age-standardised incidence rates over a specified interval estimated from joinpoint regression. |
|
| Sources : | Census and Statistics Department Department of Health Hong Kong Cancer Registry, Hospital Authority |
|
Mortality
Liver cancer was the third leading cause of cancer deaths in Hong Kong. In 2024, a total of 1 377 people died from this cancer, accounting for 9.1% of all cancer deaths. The crude death rates of liver cancer were 28.9 for males and 9.4 for females per 100 000 population of respective sex. The age-standardised death rates* of liver cancer were 12.2 for males and 3.5 for females per 100 000 standard population.
Trend of mortality
The age-standardised death rate of liver cancer of both sexes, males and females all had a downward trend over the past 44 years (average annual percentage change (AAPC)# between 1981 and 2024: -2.3%, -2.3% and -2.1% respectively) and over the past 10 years (AAPC between 2015 and 2024: -4.8%, -4.4% and -4.6% respectively).
Number of registered deaths and crude death rate of liver cancer by sex, 1981 to 2000 （View）
Number of registered deaths and crude death rate of liver cancer by sex, 2001 to 2024 （View）
Age-standardised death rate of liver cancer by sex, 1981 to 2024
| Notes : | Classification of diseases and causes of death is based on the International Statistical Classification of Diseases and Related Health Problems (ICD) 10th Revision from 2001 onwards. Figures from 2001 onwards may not be comparable with figures for previous years which were compiled based on the ICD 9th Revision. |
|
| * | Age-standardised death rates are compiled based on the world standard population specified in GPE Discussion Paper Series: No.31, EIP/GPE/EBD, World Health Organization, 2001. |
|
| # | AAPC of age-standardised death rates is a summary measure of the trends in the age-standardised death rates over a specified interval estimated from joinpoint regression. |
|
| Sources : | Census and Statistics Department Department of Health |
|
Liver cancer corresponds to codes 155 in ICD-9 and C22 in ICD-10.
For more information about cancer statistics in Hong Kong, please visit the website of the Hong Kong Cancer Registry.
For health information relating to cancer, please visit the Cancer Online Resource Hub.